FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912910191> ?p ?o ?g. }

• W2912910191 endingPage "1271" @default.
• W2912910191 startingPage "1262" @default.
• W2912910191 abstract "Abstract Aims/Introduction Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long‐term Use is an ongoing postmarketing study of ipragliflozin for long‐term use in Japanese patients with type 2 diabetes mellitus. A subgroup analysis of data from the study was carried out to investigate the impact of obesity on the efficacy and safety of ipragliflozin in this population. Materials and Methods Patients were divided into the following subgroups according to their body mass index ( BMI ): <22.0, 22.0 to <25.0, 25.0 to <30.0 and ≥30.0 kg/m 2 . Changes in bodyweight and glycemic parameters up to 3 months were evaluated, as well as adverse drug reactions ( ADR s) that occurred during ipragliflozin treatment. Results In the efficacy analysis set (8,633 patients), glycemic control and bodyweight statistically significantly improved from baseline to 3 months in all BMI subgroups (all P < 0.05). No strong correlations were identified between changes in bodyweight and changes in hemoglobin A1c, waist circumference or BMI in any of the subgroups. The incidence of adverse drug reactions was 6.29, 8.44, 11.18 and 11.74% in the <22.0, 22.0 to <25.0, 25.0 to <30.0 and ≥30.0 kg/m 2 groups, respectively ( P = 0.001), in the safety analysis set ( n = 11,053 patients). Conclusions In Japanese patients with type 2 diabetes mellitus, ipragliflozin improved glycemic control and reduced bodyweight, regardless of BMI . Adverse drug reactions were more common in patients with higher BMI than in those with lower BMI ." @default.
• W2912910191 created "2019-02-21" @default.
• W2912910191 creator A5005853008 @default.
• W2912910191 creator A5029105612 @default.
• W2912910191 creator A5061764808 @default.
• W2912910191 creator A5063103432 @default.
• W2912910191 creator A5070737875 @default.
• W2912910191 date "2019-03-25" @default.
• W2912910191 modified "2023-10-14" @default.
• W2912910191 title "Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3‐month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long‐term Use study" @default.
• W2912910191 cites W1557519555 @default.
• W2912910191 cites W1567871412 @default.
• W2912910191 cites W1595418935 @default.
• W2912910191 cites W1850744093 @default.
• W2912910191 cites W1974463975 @default.
• W2912910191 cites W1979585690 @default.
• W2912910191 cites W1988198379 @default.
• W2912910191 cites W1994014704 @default.
• W2912910191 cites W1996001084 @default.
• W2912910191 cites W2058473208 @default.
• W2912910191 cites W2074422939 @default.
• W2912910191 cites W2086860898 @default.
• W2912910191 cites W2092380707 @default.
• W2912910191 cites W2093133419 @default.
• W2912910191 cites W2108904801 @default.
• W2912910191 cites W2149461532 @default.
• W2912910191 cites W2215514440 @default.
• W2912910191 cites W2216866389 @default.
• W2912910191 cites W2337339674 @default.
• W2912910191 cites W2504665514 @default.
• W2912910191 cites W2544019344 @default.
• W2912910191 cites W2763206948 @default.
• W2912910191 cites W2768955057 @default.
• W2912910191 cites W2793653403 @default.
• W2912910191 cites W2804715956 @default.
• W2912910191 cites W2808467887 @default.
• W2912910191 cites W2912910191 @default.
• W2912910191 doi "https://doi.org/10.1111/jdi.13021" @default.
• W2912910191 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6717900" @default.
• W2912910191 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30719865" @default.
• W2912910191 hasPublicationYear "2019" @default.
• W2912910191 type Work @default.
• W2912910191 sameAs 2912910191 @default.
• W2912910191 citedByCount "5" @default.
• W2912910191 countsByYear W29129101912019 @default.
• W2912910191 countsByYear W29129101912020 @default.
• W2912910191 countsByYear W29129101912021 @default.
• W2912910191 countsByYear W29129101912023 @default.
• W2912910191 crossrefType "journal-article" @default.
• W2912910191 hasAuthorship W2912910191A5005853008 @default.
• W2912910191 hasAuthorship W2912910191A5029105612 @default.
• W2912910191 hasAuthorship W2912910191A5061764808 @default.
• W2912910191 hasAuthorship W2912910191A5063103432 @default.
• W2912910191 hasAuthorship W2912910191A5070737875 @default.
• W2912910191 hasBestOaLocation W29129101911 @default.
• W2912910191 hasConcept C120665830 @default.
• W2912910191 hasConcept C121332964 @default.
• W2912910191 hasConcept C126322002 @default.
• W2912910191 hasConcept C134018914 @default.
• W2912910191 hasConcept C187960798 @default.
• W2912910191 hasConcept C197934379 @default.
• W2912910191 hasConcept C2776193436 @default.
• W2912910191 hasConcept C2777180221 @default.
• W2912910191 hasConcept C2779306644 @default.
• W2912910191 hasConcept C2780221984 @default.
• W2912910191 hasConcept C2780473172 @default.
• W2912910191 hasConcept C2908647359 @default.
• W2912910191 hasConcept C2910068830 @default.
• W2912910191 hasConcept C44249647 @default.
• W2912910191 hasConcept C511355011 @default.
• W2912910191 hasConcept C535046627 @default.
• W2912910191 hasConcept C555293320 @default.
• W2912910191 hasConcept C61511704 @default.
• W2912910191 hasConcept C61943457 @default.
• W2912910191 hasConcept C71924100 @default.
• W2912910191 hasConcept C99454951 @default.
• W2912910191 hasConceptScore W2912910191C120665830 @default.
• W2912910191 hasConceptScore W2912910191C121332964 @default.
• W2912910191 hasConceptScore W2912910191C126322002 @default.
• W2912910191 hasConceptScore W2912910191C134018914 @default.
• W2912910191 hasConceptScore W2912910191C187960798 @default.
• W2912910191 hasConceptScore W2912910191C197934379 @default.
• W2912910191 hasConceptScore W2912910191C2776193436 @default.
• W2912910191 hasConceptScore W2912910191C2777180221 @default.
• W2912910191 hasConceptScore W2912910191C2779306644 @default.
• W2912910191 hasConceptScore W2912910191C2780221984 @default.
• W2912910191 hasConceptScore W2912910191C2780473172 @default.
• W2912910191 hasConceptScore W2912910191C2908647359 @default.
• W2912910191 hasConceptScore W2912910191C2910068830 @default.
• W2912910191 hasConceptScore W2912910191C44249647 @default.
• W2912910191 hasConceptScore W2912910191C511355011 @default.
• W2912910191 hasConceptScore W2912910191C535046627 @default.
• W2912910191 hasConceptScore W2912910191C555293320 @default.
• W2912910191 hasConceptScore W2912910191C61511704 @default.
• W2912910191 hasConceptScore W2912910191C61943457 @default.
• W2912910191 hasConceptScore W2912910191C71924100 @default.
• W2912910191 hasConceptScore W2912910191C99454951 @default.
• W2912910191 hasFunder F4320323024 @default.

• next